ANTI-HUMAN CD52 IMMUNOGLOBULINS

Title:

ANTI-HUMAN CD52 IMMUNOGLOBULINS

Document Type and Number:

Japanese Patent JP2018029624

Kind Code:

A

Abstract:

PROBLEM TO BE SOLVED: To provide anti-human CD52 immunoglobulins.SOLUTION: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.SELECTED DRAWING: None

More Like This:

WO/1996/031523	COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES, METHOD FOR PREPARING SAME, AND SYNTHON USED THEREIN
JP4863874	AAV vector for in vivo gene therapy for rheumatoid arthritis
WO/1997/048819	CASSAVA VEIN MOSAIC VIRUS PROMOTERS AND USES THEREOF

Inventors:

BRUCE L ROBERTS
SRINIVAS SHANKARA
WILLIAM HAROLD BRONDYK
WILLIAM M SIDERS

Application Number:

JP2017231850A

Publication Date:

March 01, 2018

Filing Date:

December 01, 2017

Export Citation:

Click for automatic bibliography generation Help

Assignee:

GENZYME CORP

International Classes:

C12N15/09; A61K31/436; A61K38/19; A61K39/395; A61K45/00; A61K48/00; A61P9/00; A61P19/02; A61P25/00; A61P29/00; A61P35/00; A61P35/02; A61P37/02; A61P37/04; C07K16/28; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12P21/08

Attorney, Agent or Firm:

Hidesaku Yamamoto
Natsuki Morishita

Previous Patent: A hominization nonhuman animal which has the limited immunoglobulin heavy chain gene seat

Next Patent: A human antibody to a Clostridium difficile toxin